REIG JOFRE publishes its 2025 first half financial results
REIG JOFRE CLOSES THE FIRST HALF WITH €167.4 MILLION IN REVENUE AND STRONG INTERNATIONAL AND OPERATIONAL PERFORMANCE, DESPITE THE TEMPORARY IMPACT ON THE ANTIBIOTICS BUSINESS
- REIG JOFRE is navigating a transitional year, driven by strategic decisions, industrial investments, operational strengthening, and international consolidation — all aimed at maximizing profitable growth.
- Revenue for the first half of 2025 declined by 3%, mainly due to a temporary reduction in antibiotic production.
- EBITDA reached €14.2 million, impacted by lower production linked to ongoing investments in capacity expansion, operational improvements, and regulatory adaptation, particularly at the Toledo plant. The EBITDA margin stood at 8.5%.
- International markets remain the key growth driver, accounting for 57% of total revenue — a year-on-year increase of 100 basis points.
- The company maintained its commitment to industrial investment, reaching €10.8 million in the first half of the year, mainly allocated to the Toledo facility.
- REIG JOFRE has joined the first European IPCEI in health to develop advanced therapies addressing antimicrobial resistance and rare diseases. The company received the €13 million grant yesterday.
REIG JOFRE, (BME:RJF), a pharmaceutical company listed on the Spanish Stock Exchange (BME), closed the first half of 2025 with sales of 167.4 million euros, representing a slight drop of -3% compared to the same period of the previous year, due to a temporary lower production of antibiotics, especially at the Toledo plant.
EBITDA was 14.2 million euros, with an EBITDA margin of 8.5%, and net profit amounted to 1.5 million euros. The company looks to 2025 as a key year, focused on strategic decisions, industrial investments and strengthening operations, with the aim of maximizing profitable growth, advancing international expansion, and strengthening cash generation.
Industrial investments for operational improvements and regulatory adaptation
During the first half of the year, the company intensified its industrial investments to the tune of 10.8 million euros, aimed at optimizing processes, expanding production capacity, and adapting the Toledo plant to the new EU GMP Annex 1 standards[1].
These improvements have entailed a temporary reduction in antibiotic manufacturing capacity, with a one-off impact on sales and earnings.
[1] *Regulations governing the manufacture of sterile medicinal products in the European Union, with a focus on contamination control and microbiological quality